SCHEMBL7142919

SCHEMBL7142919

CC(C)C=C(Br)Br

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1914791 0.72 TSHR (0.30)
SCHEMBL1914792 0.72 TSHR (0.30)
SCHEMBL12551867 0.72
SCHEMBL13961762 0.72
SCHEMBL14266496 0.72
SCHEMBL13062900 0.72
SCHEMBL8279762 0.72
SCHEMBL12587632 0.69
SCHEMBL12586335 0.69
SCHEMBL7074039 0.69

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6512130-B1 The present invention relates to the analogue, 11 beta -(4-(N,N- dimethylamino) phenyl)-17 beta -hydroxy-17 alpha -(3-methyl-1- butynyl)-estra-4,9-dien-3-one, of the structural formula 1 COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2003-01-28 US claimed
CN-111689993-B Novel method for preparing chiral alpha-amino boric acid ester as key intermediate of boron-containing zomib drug 凯特立斯(深圳)科技有限公司 2023-04-14 CN disclosed
CN-111689993-A Novel preparation method of chiral alpha-amino boric acid ester as key intermediate of boron-containing zomib drug 凯特立斯(深圳)科技有限公司 2020-09-22 CN disclosed
US-9949949-B2 Macrocyclic ghrelin receptor modulators and methods of using the same OCERA THERAPEUTICS, INC. (US) 2018-04-24 US disclosed
US-9920048-B2 Substituted pyrimidines for inhibiting Raf kinase activity MILLENNIUM PHARMACEUTICALS, INC. (US) 2018-03-20 US disclosed
US-20170158686-A1 Compounds Useful as Raf Kinase Inhibitors MILLENNIUM PHARMACEUTICALS, INC. (US) 2017-06-08 US disclosed
US-20170042858-A1 MACROCYCLIC GHRELIN RECEPTOR MODULATORS AND METHODS OF USING THE SAME MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY 2017-02-16 US disclosed
US-9556177-B2 Substituted 1,3-thiazoles as synthetic intermediates for preparation of Raf kinase inhibitors MILLENNIUM PHARMACEUTICALS, INC. (US) 2017-01-31 US disclosed
US-20150080568-A1 COMPOUNDS USEFUL AS RAF KINASE INHIBITORS XOMA (US) LLC 2015-03-19 US disclosed
US-8802657-B2 Compounds useful as Raf kinase inhibitors MILLENNIUM PHARMACEUTICALS, INC. (US) 2014-08-12 US disclosed
EP-1067930-A1 ANTAGONISTS OF GONADOTROPIN RELEASING HORMONE Merck & Co., Inc. (US) 2001-01-17 EP disclosed
WO-1999051232-A1 ANTAGONISTS OF GONADOTROPIN RELEASING HORMONE MERCK & CO., INC. (US) 1999-10-14 WO disclosed
WO-1999051233-A1 ANTAGONISTS OF GONADOTROPIN RELEASING HORMONE MERCK & CO., INC. (US) 1999-10-14 WO disclosed
US-5128464-A 6,6-ethylenedioxy-22R-hydroxy-2R,3S-isopropylidendioxy-5α-cholst-23-yne FUJI YAKUHIN KOGYO KABUSHIKI KAISHA (JP) 1992-07-07 US disclosed
EP-0201042-B1 3ALPHA,5-CYCLO-22,23-DIHYDROXY-5ALPHA,STEROID COMPOUNDS FUJI YAKUHIN KOGYO KABUSHIKI KAISHA (JP) 1991-08-28 EP disclosed
US-4861875-A 3α,5-cyclo-22,23-dihydroxy-5α-steroid compounds FUJI YAKUHIN KOGYO KABUSHIKI KAISHA (JP) 1989-08-29 US disclosed
EP-0201042-A2 3alpha,5-Cyclo-22,23-dihydroxy-5alpha,steroid compounds FUJI YAKUHIN KOGYO KABUSHIKI KAISHA (JP) 1986-11-12 EP disclosed
EP-0016505-B1 PROCESS FOR THE PREPARATION OF DIHALOVINYL COMPOUNDS SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) 1983-03-23 EP disclosed
US-4307243-A Process of preparing dihalovinyl compounds SHELL OIL COMPANY (US) 1981-12-22 US disclosed
EP-0016505-A1 Process for the preparation of dihalovinyl compounds SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) 1980-10-01 EP disclosed